Safety, immunogenicity, and protective efficacy of the intranasal live pertussis vaccine GamLPV in an infant monkey model (Papio hamadryas)

INTRODUCTION. The current progressive increase in pertussis incidence and infant mortality rates is due to the insufficient effectiveness of existing vaccines, both in Russia and worldwide. Previous clinical trials showed that healthy adult volunteers developed long-term antibacterial immunity after vaccination with GamLPV, an intranasal recombinant live pertussis vaccine developed by the National Research Center for Epidemiology and Microbiology named after the honorary academician N. F. Gamaleya. Further clinical development of GamLPV in paediatric volunteers, including infants, requires preclinical studies in a newborn monkey model.

AIM. This study aimed to evaluate the safety, immunogenicity, and protective efficacy of the GamLPV vaccine in infant hamadryas baboons (Papio hamadryas) challenged with pertussis after intranasal vaccination.

MATERIALS AND METHODS. The study used 20 hamadryas baboons, including 7 infants aged 1–1.5 months, 7 mothers of these infants, and 6 control animals. The study examined the time course of changes in serum levels of specific IgG antibodies to pertussis toxin (PT) and filamentous haemagglutinin (FHA) by enzyme-linked immunosorbent assay (ELISA), monitored changes in serum levels of Bordetella pertussis antibodies by agglutination immunoassay, and detected B. pertussis DNA in oropharyngeal aspirates by real-time polymerase chain reaction.

RESULTS. Intranasal GamLPV administration to infant baboons induced the production of specific IgG antibodies to PT and FHA (ELISA) and an increase in the total pertussis antibody titre (agglutination immunoassay). GamLPV did not cause any injection site or systemic reactions. There were no changes in complete blood counts and serum biochemistry profiles after vaccination. The protective efficacy of GamLPV against B. pertussis was demonstrated in challenge tests, where immunised animals had no clinical signs or laboratory findings indicative of pertussis in contrast to controls.

CONCLUSIONS. The study demonstrated the safety and immunogenicity of the intranasal live pertussis vaccine GamLPV in newborn hamadryas baboons. GamLPV shows promise in the primary vaccination of infants, the revaccination of children and adults, and the development of herd immunity against pertussis in families.

1. Macina D, Evans KE. Bordetella pertussis in school-age child­ren, adolescents, and adults: a systematic review of epidemiology, burden, and mortality in Africa. Infect Dis Ther. 2021;10(3):1097–113. https://doi.org/10.1007/s40121-021-00442-6

2. Macina D, Evans KE. Bordetella pertussis in school-age children, adolescents and adults: a systematic review of epidemiology and mortality in Europe. Infect Dis Ther. 2021;10(4):2071–118. https://doi.org/10.1007/s40121-021-00520-9

3. Basov AA, Vysochanskaya SO, Tsvirkun OV, Belova TR, Aduguzelov SE, Zhernov YuV, et al. Criteria for assessing the epidemiological situation of pertussis in Russian Federation. Epidemiology and Vaccinal Prevention. 2024;23(1):4–13 (In Russ.). https://doi.org/10.31631/2073-3046-2024-23-1-4-13

4. Warfel JM, Zimmerman LI, Merkel TJ. Acellular pertussis vaccines protect against disease but fail to prevent infection and transmission in a nonhuman primate model. Proc Natl Acad Sci USA. 2014;111(2):787–92. https://doi.org/10.1073/pnas.1314688110

5. Semin EG, Sinyashina LN, Medkova AYu, Karataev GI. Construction of recombinant attenuated Bordetella pertussis bacteria of ptxP3 genotype. Journal of Microbiology, Epidemiology and Immunobiology. 2018;(4):33–41 (In Russ.). https://doi.org/10.36233/0372-9311-2018-4-33-41

6. Li R, Lim A, Ow ST, Phoon MC, Locht C, Chow VT, et al. Development of live attenuated Bordetella pertussis strains expressing the universal influenza vaccine candidate M2e. Vaccine. 2011;29(33):5502–11. https://doi.org/10.1016/j.vaccine.2011.05.052

7. Jahnmatz M, Richert L, Al-Tawil N, Storsaeter J, Colin C, Bauduin C, et al. Safety and immunogenicity of the live attenuated intranasal pertussis vaccine BPZE1: a phase 1b, double-blind, randomised, placebo-controlled dose-escalation study. Lancet Infect Dis. 2020;20(11):1290–301. https://doi.org/10.1016/S1473-3099(20)30274-7

8. Djidaryan AA, Matua AZ, Medkova AYu, Semin EG, Sinyashina LN, Dyakov IN, et al. Safety and immunogenicity of live intranasal pertussis vaccine GamLVP in the experimental infant hamadryas baboon model. Journal of Micro­biology, Epidemiology and Immunobiology. 2022;99(2):203–14 (In Russ.). https://doi.org/10.36233/0372-9311-190

9. Kubrava DT, Medkova AYu, Sinyashina LN, Shevtsova ZV, Matua AZ, Kondzharia IG, et al. Experimental whooping cough of nonhuman primate. Annals of the Russian Academy of Medical Sciences. 2013;68(8):28–33 (In Russ.). https://doi.org/10.15690/vramn.v68i8.720

10. National Research Council (US), Committee for the Update of the Guide for the Care and Use of Laboratory Animals. Guide for the care and use of laboratory animals. 8th ed. Washington (DC): National Academies Press (US); 2011.

11. Medkova AYu, Sinyashina LN, Rumyantseva YuP, Voronina OL, Kunda MS, Karataev GI. Accumulation of avirulent Bordetella pertussis Вvg-mutants in the course of experimental whooping cough in mice. Molecular Genetics, Microbio­logy and Virology. 2013;28(4):156–61. EDN: RTWART

12. Nesterova YuV, Medkova AYu, Babachenko IV, Semin EG, Kalisnikova EL, Sinyashina LN, Karataev GI. Clinical-­diagnostic value of Bordetella pertussis genetic markers in contact persons in familial foci. Journal Infectology. 2019;11(1):17–24 (In Russ.). https://doi.org/10.22625/2072-6732-2019-11-1-17-24

13. Medkova AYu, Sinyashina LN, Amichba AA, Semin EG, Shevtsova ZV, Matua AZ et al. Preclinical studies of safety, immunogenicity and protective activity of attenuated Bordetella pertussis bacteria on the Macaca mulatta model. Journal of Microbiology, Epidemiology and Immunobiology. 2020;97(4):312–23 (In Russ.). https://doi.org/10.36233/0372-9311-2020-97-4-3

14. Medkova AYu, Lidzhieva AA, Semin EG, Sinyashina LN, Sioundioukova RA, Dyakov IN, et al. A clinical study of the safety and tolerability of live nasal vaccines for the prevention of pertussis. Drug Development & Registration, 2021;10(1):114–9 (In Russ.). https://doi.org/10.33380/2305-2066-2021-10-1-114-119

15. Karataev GI, Sinyashina LN, Medkova AYu, Semin EG, Shevtsova ZV, Matua AZ et al. Insertional inactivation of virulence operon in population of persistent Bordetella pertussis bacteria. Russian Journal of Genetics. 2016;52(4):370–7. https://doi.org/10.7868/S0016675816030085

16. Medkova AYu, Lidzhiyeva AA, Semin EG, Sinyashina LN, Syundyukova RA, Snegireva NA et al. Immunogenicity of the drug “Live intranasal vaccine for the prevention of pertussis” (GamLPV) with a single use in healthy volunteers. Journal of Microbiology, Epidemiology and Immunobiology. 2021;98(6):706–20 (In Russ.). https://doi.org/10.36233/0372-9311-194

17. Kilgore PE, Salim AM, Zervos MJ, Schmitt HJ. Pertussis: microbiology, disease, treatment, and prevention. Clin Microbiol Rev. 2016;29(3):449–86. https://doi.org/10.1128/CMR.00083-15